Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1989; 62(02): 807-810DOI: 10.1055/s-0038-1646908 Scientific and Standardization Committee Communications Schattauer GmbH Stuttgart The Utility of Plasma Fibrinopeptide Assays John Owen For the Fibrinogen Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis › Author Affiliations Recommend Article Abstract PDF Download Buy Article PDF (879 kb) References References 1 Nossel HL, Yudelman I, Canfield RE, Butler Jr VP, Spanondis K, Wilner GD, Qureshi GD. Measurement of fibrinopeptide A in human blood. J Clin Invest 1974; 54: 43-53 2 Holvoet P, Lijnen HR, Collen D. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion. Blood 1986; 67: 1482-1487 3 Kockum C, Frebelius S. Rapid radioimmunoassay of human fibrinopeptide A - removal of cross-reacting fibrinogen with bentonite. Thromb Res 1980; 19: 589-598 4 Eckhardt T, Nossel HL, Hurlet Jensen A, LaGamma KS, Owen J, Auerbach M. Measurement of desarginine fibrinopeptide B in human blood. J Clin Invest 1981; 67: 809-816 5 Nichols AB, Owen J, Kaplan KL, Sciacca RR, Cannon PJ, Nossel HL. Fibrinopeptide A, platelet factor 4, and beta-thromboglobulin levels in coronary heart disease. Blood 1982; 60: 650-654 6 Leeksma OC, Meijer Huizinga F, Stoepman van Dalen EA, van Ginkel CJ, van Aken WG, van Mourik JA. Fibrinopeptide A and the phosphate content of fibrinogen in. venous thromboembolism and disseminated intravascular coagulation. Blood 1986; 67: 1460-1467 7 Koehn JA, Canfield RE. Purification of human fibrinopeptides by high-performance liquid chromatography. Anal Biochem 1981; 116: 349-356 8 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. A monoclonal antibody with ability to distinguish between NH2-terminal fragments derived from fibrinogen and fibrin. Mol Immunol 1983; 20: 1191-1200 9 Canfield RE, Dean J, Nossel HL, Butler Jr VP, Wilner GD. Reactivity of fibrinogen and fibrinopeptide A containing fibrinogen fragments with antisera to fibrinopeptide A. Biochemistry 1976; 15: 1203-1209 10 Nossel HL, Butler Jr VP, Wilner GD, Canfield RE, Harfenist EJ. Specificity of antisera to human fibrinopeptide A used in clinical fibrinopeptide A assays. Thromb Haemostas 1976; 35: 101-109 11 Wilner GD, Nossel HL, Canfield RE, Butler Jr VP. Immunochemical studies of human fibrinopeptide A using synthetic peptide homologues. Biochemistry 1976; 15: 1209-1213 12 Bilezikian SB, Nossel HL. Unique pattern of fibrinogen cleavage by human leukocyte proteases. Blood 1977; 50: 21-28 13 Weitz JI, Landman SL, Crowley KA, Birken S, Morgan FJ. Development of an assay for in vivo neutrophil elastase activity. Increased elastase activity in patients with alpha-1-proteinase inhibitor deficiency. J Clin Invest 1986; 78: 155-162 14 Mombelli G, Roux A, Haeberli A, Straub PW. Comparison of 125I- fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias. Blood 1982; 60: 381-388 15 Peuscher FW, Cleton FJ, Armstrong L, Stoepman van Dalen EA, Van Mourik JA, van Aken WG. Significance of plasma fibrinopeptide A (fpA) in patients with malignancy. J Lab Clin Med 1980; 96: 5-14 16 Owen J, Friedman KD, Grossman B, Wilkins C, Berke AD, Powers ER. Quantitation of fragment X formation during thrombolytic therapy with streptokinase and with tissue plasminogen activator. J Clin Invest 1987; 79: 1642-1647 17 Alkjaersig N, Fletcher AP. Catabolism and excretion of fibrinopeptide A. Blood 1982; 60: 148-156
